CD73 Inhibitors Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Inhibitors by Drug Modality

CD73 inhibitors present significant opportunities in cancer immunotherapy by reversing immunosuppression in tumors and enhancing immune response. Novel antibodies, RNA, and small molecules are in ...

TL1A Inhibitors & DR3 Antagonists Competitor Analysis Report 2026: Monospecific, Bispecific, and Trispecific Antibodies Targeting TL1A/DR3, with Active R&D Programs

The market opportunities for TL1A Inhibitors and DR3 Antagonists focus on their potential to address inflammatory bowel disease, evidenced by heightened interest from major pharmaceutical companies.

Complement C5 Inhibitors & C5 Receptor Antagonists Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Targeted Immunotherapies by Drug ...

Emerging opportunities in the C5 inhibitor market include advances in biosuperiors and biosimilars, targeting a range of C5-mediated diseases such as PNH and aHUS. Innovations focus on enhancing ...

TSLP Inhibitors and TSLP Receptor Antagonists Competitor Analysis Report 2026: Latest TSLP Inhibitor and TSLP Receptor Antagonist R&D Programs by R&D Phase in a Tabular Format

TSLP inhibitors and receptor antagonists present significant market opportunities for treating various inflammatory diseases due to their ability to modulate key inflammatory pathways. Expanding ...

Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%

This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates in early-stage clinical ...
Business Wire

Parabilis Medicines to Present Trial-in-Progress Poster on Phase 1/2 Study of FOG-001, a β-catenin TCF4 Inhibitor, at ASCO Gastrointestinal Cancers Symposium

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parabilis Medicines (formerly Fog Pharmaceuticals), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with ...